Sunday, December 14, 2025 | 02:36 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Swiftly waning Covid-19 immunity poses challenge for vaccine developers

More than 100 research teams and companies around the world are seeking to develop vaccines against Covid-19, and at least 17 are already in human trials to test efficacy

covid, coronavirus, vaccine, drug, pharma
premium

Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation

Reuters London
Emerging evidence that the body's immune defence against Covid-19 may be short-lived makes it even harder for vaccine developers to come up with shots fully able to protect people in future waves of infection, scientists said on Tuesday.

Preliminary studies in China, Germany, Britain and elsewhere have found that patients infected with the novel coronavirus make protective antibodies as part of their immune system's defences, but these appear to last only a few months.

"Most people make them (antibodies), but often they can wane rather rapidly, suggesting there could be little immunity," said Daniel Altmann, a professor of immunology at